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Abstract
The use of thiopurines as immunosuppression for the 
treatment of refractory or chronic active inflammatory 
bowel disease is established for both Crohn's disease 
and ulcerative colitis. Nevertheless, many questions 
remain concerning the optimal treatment regimens of 
azathioprine, 6-mercaptopurine and thioguanine. We 
will briefly summarize dose recommendations, indica-
tions for thiopurine therapy and side effects which are 
relevant in clinical practice. We discuss some currently 
debated topics, including the combination of azathio-
prine and allopurinol, switching of thiopurine therapy in 
case of side effects, the use of azathioprine in pregnan-
cy, the infection risk using thiopurines and the evidence 
when to stop thiopurines. Excellent reviews have been 
published on the thiopurine metabolic pathway which 
will not be discussed here in detail. 
© 2013 Baishideng. All rights reserved.
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DOSING AND MONITORING OF 
THIOPURINES
Thiopurines used for inflammatory bowel disease (IBD) 
treatment are azathioprine (AZA), 6-mercaptopurine 
(6-MP) and occasionally also 6-thioguanine (6-TG). The 
most commonly used thiopurine is AZA. The hepatic 
enzyme glutathione-S-transferase rapidly cleaves the pro-
drug AZA to 6-MP[1], which is then metabolized in 
both liver and gut by several enzymes: (1) thiopurine-s-
methyltransferase (TPMT) catalysing 6-MP to 6-methyl-
MP (6-MMP); (2) xanthine oxidase catalyzing 6-MP to 
thiourea; and (3) hypoxanthine-guanine-phosphoribo-
syltransferase converting 6-MP to 6-thioguanine nucle-
otides (6-TGN). 6-TG is the final effector-metabolite[2] 
which slowly accumulates in cells, and this metabolite is 
probably responsible for the delayed onset of  action af-
ter 10-12 wk[3].
Dose recommendations for AZA and 6-MP vary slight-
ly between Western guidelines, with a daily dose of  2-3 
mg/kg AZA and 1-1.5 mg/kg 6-MP recommended by 
the AGA[4], and a daily dose of  1.5-2.5 mg/kg AZA and 
0.75-1.5 mg/kg 6-MP recommended by the European 
Crohn’s and Colitis Organisation (ECCO)[5]. However, 
these recommendations do not necessarily hold true for 
other ethnicities. Several Japanese studies showed that 
Japanese IBD patients might reach sufficient 6-TGN val-
ues with substantially lower AZA and 6-MP dosages in 
adults[6,7], children and adolescents[8]. If  6-TG is excep-
tionally used, it should be started at a much lower dosage 
of  approximately 20 mg per day and should not exceed 
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25 mg daily[9]. However, it has to be strengthened that 
there are limited indications for use of  6-TG in IBD. 
6-TG can be used in IBD patients who need a thiopu-
rine for maintenance therapy but who are intolerant (or 
resistant) to 5-aminosalicylic acid (5-ASA) [in ulcerative 
colitis (UC)], AZA, 6-MP and methotrexate [in Crohn’s 
disease (CD)], and who do not have an option for sur-
gery[9]. Biological therapy could be considered as an al-
ternative to 6-TG in this setting. The ECCO guidelines[5] 
concluded in 2006 that thioguanine cannot currently be 
recommended for maintenance of  CD due to a high fre-
quency of  liver abnormalities (mainly nodular regenera-
tive hyperplasia). According to the current literature, this 
might, however, be explained by the use of  too high dos-
ages of  6-TG resulting in 6-TGN levels exceeding 1000 
pmol/8 × 108 erythrocytes which is much more than the 
target levels of  250-500 pmol/8 × 108 erythrocytes usu-
ally recommended when using AZA or 6-MP[10-12]. Thus, 
if  6-TG is used as therapy for selected IBD patients, the 
6-TGN levels should be controlled regularly combined 
with close monitoring of  liver values[13], hematology and 
especially liver biopsy after one, three and then every 
three years[9]. However, the histopathological diagnosis 
of  nodular regenerative hyperplasia is difficult with a 
very poor inter-observer agreement, even among ex-
perts[14]. Alternatively, non-invasive monitoring such as 
magnetic resonance imaging may be considered[15]. 
The dose recommendations as mentioned above are 
based on “Western” or “Caucasian” guidelines/eviden-
ce and are linked to the assumption that the TPMT 
pathway is “normal”. A diminished TPMT activity due 
to mutations of  the TPMT gene leads to toxic levels of  
6-TGN, which is a risk factor for drug-induced myelo-
suppression[16]. TPMT mutations are not uncommon in 
Caucasian populations (mutation prevalence approxi-
mately 10%), but rarer in e.g., Chinese patients (5%) or 
even very rare in Japanese patients (1%)[17], which ques-
tions the usefulness of  routine TPMT monitoring in 
these patients. The role of  pharmacogenetics has recent-
ly been addressed in an excellent review by Chouchana et 
al[18] and is shortly summarized below. 
To achieve an optimal therapy, it seems crucial to find 
the correct concentration of  intracellular 6-TGN (serum 
levels are of  no value). Concentrations that are too high 
lead to myelosuppression, whereas concentrations that 
are too low result in a lack of  efficacy in IBD[16,19]. TGN-
levels can be measured irrespective of  the time of  intake 
of  thiopurines. The commonly recommended 6-TGN 
concentration is 235-500 pmol/8 × 108 erythrocytes. In 
a meta-analysis[20], patients with 6-TGN levels above the 
threshold value of  235 were more likely to be in remis-
sion than those below the threshold value (62% vs 36%, P 
< 0.001). The usefulness of  therapeutic drug monitoring 
has recently been supported in a Dutch study[21]. How-
ever, the minimum effective dose is unknown. No dose-
response study has ever been carried out, but at least one 
study showed that an increase in AZA dosage (2.02-2.72 
mg/kg daily) can induce response in some patients[22]. 
Since there is only a very weak correlation between thio-
purine dosage and 6-TGN levels[20] and some ethnic vari-
ability[6,7], the authors believe that 6-TGN levels should 
be regularly measured. Measuring the 6-TGN levels alle-
viates uncertainties when AZA therapy is combined with 
5-ASA in UC[23]. In a recent and well-performed prospec-
tive study, the addition of  2 g of  5-ASA increased the 
total amount of  6-TGN by 50%, and methylmercaptopu-
rine ribonucleotide levels were reduced after adding 4 g 
of  5-ASA[24]. Further studies are needed to show whether 
6-TGN measurements might be useful to improve thio-
purine therapy.
TPMT MONITORING
Beside the above mentioned measurement of  thiopu-
rine metabolites, TPMT genotyping (analysis of  single 
nucleotide polymorphisms which influence the TPMT 
activity) and phenotyping (measuring the TMPT activity) 
can be applied before therapy with AZA or 6-MP is ini-
tiated. A recent study concluded that genotyping should 
be favoured for pre-treatment TPMT function since it 
is the more reliable test[25]. This evaluation may help to 
identify slow metabolizers which are at risk of  toxicity[4]. 
Nevertheless, a recently meta-analysis stated that there is 
not yet enough evidence to advocate for routine TPMT 
testing[26]. The United States Food and Drug Adminis-
tration (FDA), but not the ECCO, recommends TPMT 
monitoring before the initiation of  thiopurine therapy. 
In 2011, the first guideline for a thiopurine starting dose 
according to TPMT phenotype/genotype was devel-
oped[27]. A reduction to 30%-70% of  the full dose is 
recommended in patients with an intermediate activ-
ity (heterozygote). In patients with low/absent activity 
(homozygous mutant or compound heterozygote), an 
alternative drug should be considered or AZA starting 
dose must be reduced by a 10-fold, administered thrice 
weekly, and under close monitoring. For patients with 
intermediate and low/absent TPMT activity, a therapeu-
tic drug monitoring is recommended four weeks after 
treatment initiation. Patients with a very high activity 
might benefit from an increase in AZA dosage up to 3.0 
mg/kg per day[18]. Nevertheless, it is important to note 
that TPMT testing does not predict the long-term risk 
of  myelosuppression or idiosyncratic adverse events 
such as fever, arthralgias, hepatitis or pancreatitis[28]. 
Regular hematologic monitoring remains necessary[26], 
initially at least every second week until the patient has 
been on a stable dose for a month; in the later course at 
least every third month[29,30], including a complete blood 
count including a differential count, especially to check 
the lymphocyte level but also platelets as well as amylase, 
and liver enzyme levels[4,30,31].
INDICATIONS FOR AZATHIOPRINE OR 
6-MERCAPTOPURINE
No evidence for induction of remission in active IBD
There is not enough evidence to recommend thiopurines 
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for inducing remission in active IBD[32] based on five 
randomized controlled trials (RCTs) in active CD[33-37] 
and on two RCTs in active UC[38,39].
Prevention of relapse in quiescent IBD
In quiescent CD, AZA and 6-MP are effective at pre-
venting a relapse based on two RCTs comparing AZA 
with placebo[33,37], and three RCTs comparing continued 
AZA vs withdrawal in patients who had been success-
fully maintained on AZA[40-42]. These studies showed a 
significantly higher relapse rate in the placebo groups as 
compared with the active treatment[32]. Additionally, a 
RCT evaluating glucocorticoid-dependent CD patients 
suggested that AZA was better than placebo at reducing 
the need for glucocorticoids[43]. 
In quiescent UC, AZA and 6-MP are effective at 
preventing a relapse based on three RCTs comparing 
AZA with placebo[38,39,44]. Overall, 60% of  patients can 
be kept in remission if  AZA is continued for 9-12 mo[32]. 
Similarly, another RCT which evaluated AZA withdrawal 
in 79 patients, who had been maintained on this drug for 
a minimum of  6 mo, showed a significant reduction on 
the relapse rate on AZA vs placebo after one year (36% 
vs 59%)[45] .
Post-operative treatment of CD with thiopurines
Two RCTs in postoperative CD suggest that AZA or 
6-MP is superior to placebo at preventing recurrence 
after surgery[46,47]. Furthermore, thiopurines administered 
postoperatively significantly reduced the clinical recur-
rence rates in population-based cohorts[48,49]. Thus, thiop-
urines might be a useful strategy, although anti-tumour 
necrosis factors (anti-TNFs) might be more efficient in 
preventing CD relapses postoperatively[50,51], especially 
among high risk patients (smokers, perforating disease or 
≥ second operation)[50].
Treatment of fistulising CD with thiopurines
A meta-analysis in fistulizing CD demonstrates a sig-
nificantly higher response rate to AZA and 6-MP as 
compared to placebo (54% vs 21%)[52]. The analyzed 
studies included patients with perianal, enterocutaneous, 
enteroenteric and rectovaginal fistulas. However, only 
in a minority of  patients, AZA and 6-MP will lead to a 
complete fistula closure, but symptoms such as inflam-
mation, discharge and discomfort are often substantially 
reduced. Since response of  fistulas to these drugs will 
need several months, immunosuppression will be rea-
sonable only as second-line treatment if  fistulas don’t 
necessitate immediate surgery. Antibiotics are commonly 
used as first-line treatment and need to be started in par-
allel[53]. 
An overview of  indications for thiopurines in IBD is 
given in Table 1.
ADVERSE EVENTS
AZA and 6-MP have similar side effects leading to dis-
continuation of  therapy in 39% of  patients in a large 
Dutch cohort[54], however, rates of  intolerance are usu-
ally far lower. Most adverse events occur within the first 
3 mo[55]. More than 50% of  AZA intolerant patients 
tolerate 6-MP long-term[56]. Common side effects can be 
divided into dose-dependent and idiosyncratic side ef-
fects.
The major dose-dependent side effect of  thiopu-
rines is drug-induced myelosuppression which is ob-
served in 2%-5% of  Caucasian patients[57,58]. It can oc-
cur at any time with 25% of  cases appearing beyond the 
first year[55]. Asian (or at least Japanese patients[6,7]) have a 
higher risk of  myelotoxicity. It has been speculated that 
viral infections might contribute to myelosuppression, 
however, clear evidence is missing. Determining TPMT 
activity before starting thiopurines might avoid early 
myelosuppression, but regular haematological monitor-
ing remains necessary in every patient.
Infectious complications are mostly dose-dependent, 
but sometimes idiosyncratic side effects. Infectious com-
plications during thiopurine therapy can occur even in 
the absence of  a dose-dependent leukopenia[4,59,60], es-
pecially when using a combination of  thiopurines with 
corticosteroids which may induce a dose-dependent 
lymphocyte depletion. We recommend avoiding a lym-
phopenia of  < 600/μL based on data from a rheuma-
tological study[31]. Doing this, severe immunodeficiency 
is likely to be avoided[31] Hepatotoxicity can manifest as 
early drug-induced hepatitis, nodular regenerative hy-
perplasia after years of  therapy, sinusoidal dilatation or 
fibrosis[61]. It is important to note that IBD per se is a risk 
factor for nodular regenerative hyperplasia[62]. Hepato-
toxicity induced by thiopurines seems more often dose 
dependent than idiosyncratic. In many patients, elevated 
transaminases respond to dose reduction. In a prospec-
tive monocentric cohort, 21 of  123 patients showed a 
transient or constant elevation of  alanine aminotrans-
ferase levels[63]. If  liver enzymes are repeatedly elevated, 
thiopurines need to be discontinued.
The most frequent idiosyncratic side effects are nau-
sea, vomiting, and malaise in up to 15% of  all patients[64]. 
Some advocate to slowly increase the dosage when thi-
opurine therapy is started, or to take it before night-
time. However, the best way to start thiopurine therapy 
still has to be determined[4]. Other common side effects 
are headache, fatigue, anorexia, weight loss, stomatitis, 
alopecia, arthralgia, muscular weakness and rash, which 
may occur in more than 10% of  patients. If  these side 
effects are reported, it should be determined whether 
they disappear after dose reduction[4,59,60,65,66]. In case of  
arthralgias/myalgias upon AZA, a switch to 6-MP can 
be explored[55].
Pancreatitis is an important idiosyncratic side effect 
and occurs in up to 4% of  the patients[4,60], especially 
during the first weeks of  treatment[67]. A minor and 
asymptomatic increase in serum amylase (“pancreatic hy-
perenzymemia”) is frequently observed, but only poorly 
understood and not discussed in current guidelines. 
Some authors prefer to reduce dosing, or stop treatment 
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in case of  lack of  biochemical response[68]. Thiopurines 
must be discontinued if  amylase increase is associated 
with typical pain symptoms (i.e., toxic pancreatitis). After 
AZA-induced pancreatitis, a switch to 6-MP is not rec-
ommended since these patients are less likely to tolerate 
6-MP[64]; However, evidence against the use of  6-MP in 
AZA-induced pancreatitis is weak. As earlier outlined, 
6-TG is a debated alternative to AZA and 6-MP in case 
of  intolerance[9], which is, however, not recommended 
by some authors[69,70].
WHEN AND HOW TO CHANGE THIOPURINE 
THERAPY IN CASE OF SIDE EFFECTS?
In the case of  idiosyncratic side effects, it might be rea-
sonable to change from AZA to 6-MP, as discussed 
above. Furthermore, in so-called preferential 6-MMP 
metabolizers which achieve only low 6-TGN levels 
due to high 6-MMP levels with associated hepatotoxic-
ity, adding low-dose allopurinol as a XO inhibitor to 
dose-decreased AZA (25%-33% of  intended dose[71], 
might switch the AZA metabolism to 6-TGN instead 
of  6MMP. Close monitoring of  6-TGN metabolites 
and hematology is in such cases necessary (weekly dur-
ing the first month, then every other week for the next 
month)[69]. This strategy often allows to reach therapeu-
tic levels of  6-TGN and clinical remission, but may also 
to reduce or even alleviate nausea as one of  the major 
early side effects in more than 80% of  patients[72]. Inter-
estingly it seems possible to achieve higher 6-TGN and 
lower 6-MMP levels in preferential 6-MMP metabolizers 
by simply splitting the daily thiopurine dose[73] or by 
switching to 6-MP. 
MALIGNANT COMPLICATIONS
Treatment with AZA/6-MP is associated with a potential 
risk of  developing lymphoma[74], including hepatosplenic 
T-cell lymphoma (HSTCL)[75]. Although the relative risk 
of  lymphoma is increased four to five-fold[74,76], the ab-
solute risk still remains rather small, and currently avail-
able data show that the benefits of  thiopurines used in 
IBD greatly outweigh its risks[77]. The same holds true for 
non-melanoma skin cancer[78-80], which in a large cohort 
of  108.518 IBD patients collected from 1997 to 2009 
was shown to occur significantly more often in IBD pa-
tients on thiopurines especially among those with CD 
than controls[79], correlating with the length of  receiving 
thiopurines. Of  32 cases of  nonmelanoma skin cancer 
in a large cohort[80], only 5 cancers occurred in immuno-
modulator-naïve patients, but 9 and 18 cancers occurred 
in patients who had previously taken or were currently 
on thiopurine therapy. Based on these studies, a derma-
tologic exam should be considered before and regularly 
during immunomodulator therapy; especially in elderly 
patients. It should in this context be mentioned that skin 
protection is rather crucial. 
WHEN SHOULD THIOPURINE MONO-
THERAPY BE STOPPED?
When to stop a successful immunosuppression is one 
of  the most difficult decisions in IBD therapy. Five stud-
ies focussing on this question were recently reviewed 
by Clarke and Regueiro[81]. According to a randomized, 
controlled study from 2005, even CD patients who were 
in remission on AZA for at least 3.5 year profited from 
prolonged AZA therapy (relapse risk 8% vs 21% on 
placebo)[40]. Similar results have been gained from other 
studies[82]. Five years after stopping AZA, 3/4 of  pa-
tients suffer from relapse. Nevertheless, a treatment stop 
seems justified since almost all patients re-treated with 
thiopurines were able to regain remission (23 of  24 pa-
tients; many with a combined short course of  glucocor-
ticoids)[83]. Independent predictors for a flare are a C-re-
active protein-level of  > 20 mg/L, a haemoglobin-level 
< 12 mg/dL, and an absolute neutrophil count of  > 4 × 
109/L at baseline. Since more than half  of  the patients 
with risk factors experienced a clinical flare-up within 24 
mo (compared to only 15% of  patients without negative 
predictors), a continuous course of  thiopurine therapy is 
recommended for these patients. 
In UC, several studies have shown that a prolonged 
AZA therapy helps to reduce the risk of  relapse. Six 
months is certainly the minimum length of  immunosup-
pression (with at least 3 mo disease-free interval off  glu-
Table 1  Indications for thiopurines in inflammatory bowel disease
Indication No indication
Crohn’s disease Maintaining remission in moderate (to severe) CD (any site of disease especially for extensive disease)
Maintaining remission in CD with early relapse (< 3 mo after the last flare) or frequent flares (more than two per year)
Fistulizing CD (in combination with antibiotics, if no early start of anti-TNF or surgery necessary)
Postoperative prevention of CD recurrence (unless high-risk situation such as repeated surgery or current smoker)
In combination with anti-TNFs in case of severe CD (rapid step-up or top-down)
Induction of 
remission (as a 
sole therapy in 
active disease)
Ulcerative colitis 
(treated with 
5-ASA at optimal 
dose unless 
intolerant)
Maintaining remission in steroid-dependent UC 
Maintaining remission in UC with early relapse requiring steroids
Maintaining remission in UC with frequent flares requiring steroids
Maintaining remission in UC after induction of remission by ciclosporin, tacrolimus, or i.v. steroids
Acute or chronic refractory pouchitis
Induction of 
remission (as a 
sole therapy in 
active disease)
CD: Crohn’s disease; UC: Ulcerative colitis; TNF: Tumour necrosis factor; 5-ASA: 5-aminosalicylic acid. 
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cocorticoids)[84,85], but other studies showed that 18 mo 
is significantly better than 6 mo[81].
In clinical practice, decision on the length of  immu-
nosuppressive therapy means weighing benefits of  im-
munosuppression on IBD and risk of  malignancies and 
other complications. The risk factors should be analysed 
before immunosuppression is stopped. Best candidates 
for stopping immunosuppression will probably be IBD 
patients in deep, prolonged remission with a short dura-
tion of  time between diagnosis and immunomodulator 
treatment[81]. Nonetheless, prospective RCTs are needed 
for the development of  evidence-based tapering schemes 
regarding AZA and 6-MP treatment, both in CD as well 
as in UC. 
IMMUNOMODULATORS AND BIOLOGIC 
THERAPY
Many experts in the field currently advocate a “top 
down” approach with early combination therapy for 
moderate to severe CD based on evidence from three 
infliximab and azathioprine studies in CD[86-88], including 
the famous SONIC trial[86]. Nevertheless caution is ad-
vised as the number needed to treat for the combination 
therapy is 8, meaning that only one out of  8 patients will 
definitely benefit from the combination. For the com-
bination of  AZA and adalimumab, there are only retro-
spective and hardly convincing data[89]. Future trials need 
to determine whether it is crucial to start with anti-TNFs 
and thiopurines at the same time, or whether a sequen-
tial addition of  thiopurines to anti-TNFs will have the 
same effect in the patients experiencing a benefit from 
this combination.
Furthermore, there are not enough available data on 
how long the concomitant use of  immunomodulators 
should be maintained in patients receiving infliximab. 
There are no studies which documented a sustained effi-
cacy of  concomitant use of  immunomodulators beyond 
6-12 mo[90,91]. If  therapy should be reduced, then AZA 
and not infliximab may be stopped. In the recently pub-
lished prospective STORI (Stop Infliximab in Patients 
With Crohn’s Disease) study on infliximab stop in pa-
tients in remission under combined immunosuppression, 
nearly half  of  all patients suffered from relapse within 
1 year when infliximab was stopped despite continuing 
azathioprine[92]. In contrary, the risk of  relapse after stop-
ping AZA seems lower than after stopping infliximab. 
Thus, in a single referral center observational study on 
CD patients who stopped AZA after being in remission 
under combined AZA and infliximab for at least 6 mo, 
15% of  patients relapsed after 1 year[93]. 
THIOPURINES IN PREGNANCY AND 
LACTATION 
Even though thiopurines belong to FDA pregnancy cat-
egory D, the risk seems minimal. Two studies[94,95] did not 
find any evidence for an increased risk of  pregnancy-re-
lated complications. Probably, the only major side effect 
of  thiopurines is the risk of  preterm birth[95-97], which, 
however, might be simply a disease effect. Furthermore, 
thiopurine levels in breast milk of  mothers treated with 
AZA seem harmless[98] and without any long-term ef-
fects in these babies. Thus, it can be concluded that thio-
purines can be administered safely to women with IBD, 
prior to and at the time at conception, as well as dur-
ing pregnancy and lactation. Indeed, in a recent survey 
among gastroenterologists showed that more than 90% 
would recommend continuous thiopurine treatment[99]. 
CONCLUSION
Indications for use of  thiopurines in IBD and ways to 
monitor therapy have been well established. In clinical 
practice, the possibility of  6-TGN measurement to mon-
itor therapy seems underused. It is likely that broader use 
of  TGN monitoring, and a combination of  thiopurines 
with low dose allopurinol in case of  inefficiency or side 
effects allows to (achieve or) maintain clinical remission 
in more patients. For the thiopurine/allopurinol com-
bination, but also for 6-TG therapy, prospective trials 
to document the benefit (and risk) are urgently needed. 
Furthermore, more trials are needed to elucidate whether 
an early “top down” approach for combination of  thio-
purines with anti-TNF will bring a long-term benefit for 
patients as compared to a step-up approach in case of  a 
non-response to thiopurines. Criteria when a successful 
thiopurine therapy for maintenance of  remission can be 
stopped also need to be elucidated in future prospective 
trials. Risk communication with patients, but also refer-
ring physicians, about benefit, side effects and the above 
mentioned uncertainties remain challenging. Benefits 
are the quality of  life gained by medically maintained 
remission; the avoidance of  surgery (in CD and UC) and 
avoidance of  colorectal cancer through efficient anti-
inflammatory therapy. Risks are, however, (opportunistic) 
infections, lymphomas such as HSTCL and side-effects 
such as pancreatitis. 
Accordingly, thiopurine therapy remains a hot topic 
in IBD.
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